SCHEMBL11997508

SCHEMBL11997508

C#CC#CC#CCCCO[C@@H]1OC(CO)[C@@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3OC(CO)[C@@H](O[C@H]4C[C@H](O)C(O[C@@H]5OC(COS(=O)(=O)O)[C@@H](O[C@H]6C[C@H](O)[C@@H](OC7OC(COS(=O)(=O)O)[C@@H](O[C@H]8C[C@H](O)[C@H](O)CO8)[C@H](O)C7NC(C)=O)CO6)[C@H](O)C5NC(C)=O)CO4)[C@H](O)C3NC(C)=O)CO2)[C@H](O)C1NC(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 1/20 0.39
▸ LGALS3 P17931 1/20 0.39
▸ LGALS4 P56470 1/20 0.39
▸ BMP2 P12643 2/20 0.37
▸ VEGFA P15692 2/20 0.37
▸ CXCL12 P48061 2/20 0.37
▸ SHH Q15465 2/20 0.37
▸ BDNF P23560 3/20 0.36
▸ MDK P21741 3/20 0.36
▸ PTN P21246 2/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ SIGLEC7 Q9Y286 4/20 0.35
▸ IFNG P01579 1/20 0.34
▸ PF4 P02776 1/20 0.34
▸ CCL2 P13500 1/20 0.34
▸ SELP P16109 1/20 0.34
▸ BMP6 P22004 1/20 0.34
▸ CCL11 P51671 1/20 0.34
▸ WNT3A P56704 1/20 0.34
▸ SELPLG Q14242 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11997509 0.93 BMP2 (0.33) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997493 0.84 VEGFA (0.50) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997497 0.84 VEGFA (0.49) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997503 0.84 CD69 (0.40) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997501 0.84 CD69 (0.40) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997500 0.84 CD69 (0.40) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997502 0.84 CD69 (0.40) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL11997499 0.81 F10 (0.40) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL16656569 0.79 F10 (0.37) LGALS8LGALS3LGALS4BMP2VEGFA
SCHEMBL16656568 0.79 F10 (0.37) LGALS8LGALS3LGALS4BMP2VEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012413-B2 FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-04-21 — — US disclosed
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF FGFR1, FGF2, FGFR3 LGALS8 562/4885LGALS3 698/4885LGALS4 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback